Literature DB >> 2316788

Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study.

M G Guzmán1, G P Kouri, J Bravo, M Soler, S Vazquez, L Morier.   

Abstract

In Cuba, 2 epidemics of dengue virus occurred: 1 caused by DEN-1 in 1977 and 1 caused by DEN-2 in 1981. The latter was associated with cases of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). To study viral risk factors for DHF/DSS, a retrospective seroepidemiological survey was conducted in Cerro, a densely populated district in Havana City. The prevalence of plaque reduction neutralizing antibodies to DEN-1 and DEN-2 viruses was measured in 1,295 individuals (children and adults). Of these, 43.7% were immune to DEN-1 virus and 23.6% to DEN-2 virus. Of those individuals who were immune, 26.1% were immune to DEN-1 virus only, 6% to DEN-2 virus only, and 17.6% to both viruses. The DEN-2 virus infection rate in DEN-1 immune individuals was 3.8 times higher than in non-immune individuals. The 5 DHF/DSS cases in the sample had evidence of DEN-1 virus plus DEN-2 virus infections. Three were children and 2 were young adults. No cases were found in individuals infected with DEN-1 virus or DEN-2 virus only. Children infected by DEN-1 virus followed by DEN-2 virus had a high risk of acquiring DHF/DSS. Blacks and whites were equally infected with DEN-1 and DEN-2 viruses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2316788     DOI: 10.4269/ajtmh.1990.42.179

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  104 in total

Review 1.  Current advances in dengue diagnosis.

Authors:  Pei-Yun Shu; Jyh-Hsiung Huang
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

Review 2.  Dengue: defining protective versus pathologic immunity.

Authors:  Alan L Rothman
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

3.  Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections.

Authors:  Vanda Akico Ueda Fick de Souza; Silvana Fernandes; Evaldo Stanislau Araújo; Adriana Fumie Tateno; Olímpia M N P F Oliveira; Renato Reis Oliveira; Cláudio Sérgio Pannuti
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

4.  Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Authors:  Simona Zompi; Brian H Santich; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

5.  Validation of probability equation and decision tree in predicting subsequent dengue hemorrhagic fever in adult dengue inpatients in Singapore.

Authors:  Tun L Thein; Yee-Sin Leo; Vernon J Lee; Yan Sun; David C Lye
Journal:  Am J Trop Med Hyg       Date:  2011-11       Impact factor: 2.345

Review 6.  Dengue: a continuing global threat.

Authors:  Maria G Guzman; Scott B Halstead; Harvey Artsob; Philippe Buchy; Jeremy Farrar; Duane J Gubler; Elizabeth Hunsperger; Axel Kroeger; Harold S Margolis; Eric Martínez; Michael B Nathan; Jose Luis Pelegrino; Cameron Simmons; Sutee Yoksan; Rosanna W Peeling
Journal:  Nat Rev Microbiol       Date:  2010-12       Impact factor: 60.633

7.  Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity.

Authors:  Poornima Parameswaran; Patrick Charlebois; Yolanda Tellez; Andrea Nunez; Elizabeth M Ryan; Christine M Malboeuf; Joshua Z Levin; Niall J Lennon; Angel Balmaseda; Eva Harris; Matthew R Henn
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

Review 8.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner.

Authors:  Scott B Halstead
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 9.  Advances in dengue diagnosis.

Authors:  M G Guzmán; G Kourí
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

10.  A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Daniel Elwood; Catherine J Larsson; Janet C Lindow; Cecilia Tibery; Beulah P Sabundayo; Donna Shaffer; Kawsar R Talaat; Noreen A Hynes; Kimberli Wanionek; Marya P Carmolli; Catherine J Luke; Brian R Murphy; Kanta Subbarao; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2013-01-17       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.